Heart Failure,CongestiveROCK-HFNCT06350695
The ROle of Compression StocKings in Heart Failure Patients
A study testing low grade compression stockings (10-15 mmHg) and high grade compression stockings (20-30 mmHg) in people with Heart Failure,Congestive and Leg Edema, run by University of Maryland, Baltimore at 1 site in United States.
Trial summary
Congestive heart failure (CHF) occurs when the heart is weak and not able to effectively pump blood to the body. One of the common manifestations of CHF is fluid overload and swelling of the legs. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Heart Failure,Congestive, Leg Edema, Venous Insufficiency
- What is being tested?
- low grade compression stockings (10-15 mmHg) and high grade compression stockings (20-30 mmHg)
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 17 Jan 2024to 1 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 years and older
- Diagnosis of Heart failure NYHA II-III Class A, B, or C.
- Pitting edema of the lower extremities
Who cannot join
- Peripheral arterial disease with ABI of 0.5 or less
- Severe decompensated heart failure NYHA IV
- Unstable acute coronary syndrome
- Severe valvular stenosis or regurgitation
- Hypertrophic obstructive cardiomyopathy
- Unstable arrhythmia without a defibrillator
Show all 14Show fewer
- On renal replacement therapy, hemodialysis of peritoneal dialysis
- Morbid obesity with a BMI \> 40
- Pregnancy
- Lymphedema or Lipoedema
- Unable to put the compression stockings on by him/ herself or a person to do it for the patient
- Septic phlebitis, acute bacterial, viral or allergic inflammation of the legs
- Expectancy of life less than 6 months
- Unable to read or understand English language
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas, 75390
Rafael Cires-Drouet, MD, 214-645-2174, rafael.cires-drouet@UTSouthwestern.edu
Rafael S Cires-Drouet, MD
About this study
Congestive heart failure (CHF) occurs when the heart is weak and not able to effectively pump blood to the body. One of the common manifestations of CHF is fluid overload and swelling of the legs. Diuretics or "water pills" are usually the treatment for fluid overload and leg swelling; however, in some patients' diuretics are no longer effective or the effectiveness is limited due to poor kidney function. The presence of chronic swelling of the legs could potentially damage the veins; additionally, it could lead to chronic skin changes in the legs and in the worst cases to a leg ulcer. Compression stockings are used in patients with venous diseases to reduce the swelling of the legs and improve mobility and quality of life. Although, there is a theoretical risk that compression stockings might push the fluid of the legs back to the heart and lungs worsening the CHF. The purpose of this study is to determine whether the use of knee-high tight socks (tight stockings with strong compression) vs. knee-high soft socks (soft stockings with minimum compression) are effective in preventing swelling and skin changes and safe in patients with CHF. During the first visit (in-person) a routine medical test will be performed including blood tests, review of the medication doses, current weight, an ultrasound images of the veins, (venous reflux ultrasound), questions about health status and a brief physical exam. The participants will be randomly assigned to receive tight compression vs. soft compression socks. Participants will be asked to wear the socks at least 8 hours a day for 5 days a week. There will be a total of 3 virtual visit (by video or telephone); the first one after one week, then after one month and two months. During the virtual visit participants will be asked about symptoms, current medications and doses, and current weight. The participants are expected to return to the clinic after 3 months for a second in-person visit. During this visit the investigators will ask questions about participant's health, they will perform a brief physical exam of their legs, and check participants weight and medicines; also, a venous ultrasound of the legs, questions about health status will be performed. The duration of the study is 3 months.
Read the detailed description
Introduction Heart failure (HF) affects 6.2 million patients in the United States and was responsible of 13.4% of deaths in 2018 costing about 30.7 billion USD in 2012, and about 80% of all the patients with HF are \>65 years old. Clinical manifestations include shortness of breath and peripheral edema. Diuretics are indicated to treat edema in patients with HF, however, its use is limited in patients with compromised kidney function. Peripheral edema is associated with pain, heavy legs, limited mobility, and poor quality of life, increasing the risk of cellulitis, and wounds. Heart failure was identified in up to 44% of patients with venous ulcers. The chronic use of compression stockings in HF patients has potential benefits such as a better control of the edema, decreasing the need for diuretics, improving mobility, prevention of progression of venous disease, and prevention of venous ulcers. To date, no major HF guidelines recommend in favor or against compression stockings in HF patients.
Previous studies in patients with HF who had a pulmonary artery catheter in place, showed that compression of the lower extremities increases the right atrial pressure. However, it was a short intervention, and there was no evidence of clinical deterioration or worsening symptoms of HF. A retrospective review from a wound center showed that the use of compression therapy in HF patient was not associated with an increase in death, hospitalizations, or use of diuretics.
Hypothesis: The hypothesis is the use of compression stockings would prevent developing or worsening venous disease (venous reflux, and venous ulcers), improving the edema of the lower extremities, mobility and quality of life in HF patients without increasing the risk of HF deterioration, hospitalization, or death. To obtain preliminary information, this study proposes to randomize 30 patients with HF (New York Heart Association class II-III, stage A, B or C) on maximum medical therapy to 3 months of compression stockings 20-30 mmHg knee high (High compression group, n=15) vs. regular stocking with ≤10 mmHg of compression (Low compression group, n=15).
Aim 1. To determine whether the use of graduated 20-30 mmHg compression stockings are associated with clinical deterioration or increase is hospitalization or death in patients with HF. Patients will be evaluated at baseline, in a week after enrollment (telemedicine), and at three months. The New York Heart Association (NYHA) clinical classification, the Kansas City Cardiomyopathy Questionnaire (KCCQ), levels of brain natriuretic peptide, serum creatinine, documentation of diuretic therapy, body weight, visits to the Emergency Department, hospitalizations and deaths will be obtained on the baseline and 3-month visit. The change in NYHA clinical classification, KCCQ, body weight, diuretic dosage and any adverse events will be compared at 3 months.
AIM 2a. To evaluate if the use of graduated 20-30 mmHg compression stockings is associated with prevention of developing or worsening venous reflux. The presence of venous reflux will be documented with a venous duplex of the lower extremities looking for reflux and obstruction. The difference in time (3-month - baseline) of venous valve closure in milliseconds in bilateral common iliac, common femoral, femoral, popliteal veins, saphenous-femoral junction, great saphenous and small saphenous veins will be documented and compared between high compression and low compression stocking groups.
AIM 2b. To evaluate if the use of graduated 20-30 mmHg compression stockings is associated with prevention of developing or worsening clinical signs of venous insufficiency (C class of CEAP C1-C6). A brief physical exam of the lower extremities will be performed to obtain the C class for the CEAP classification for venous disease at baseline and 3 months. The C score will be compared between high compression and low compression stocking groups.
Aim 3. To evaluate if the use of graduated 20-30 mmHg compression stockings is associated with improvement of mobility and quality of life in heart failure patients. The quality of life will be documented using the VEINS QoL and SF-36 questionnaires; and the mobility will be assessed using the Short Physical Performance Battery test (SPPB). Patients will be evaluated at baseline and at 3-months visits. The difference in scores (3-month - baseline) will be compared between high compression and low compression stocking groups.
- Being tested
- low grade compression stockings (10-15 mmHg), high grade compression stockings (20-30 mmHg)
- Keywords
- compression stockings, congestive heart failure, venous insufficiency, edema of the legs, venous ulcers
- Medical subject headings
- Heart Failure, Venous Insufficiency, Varicose Ulcer
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
low grade compression stockings (10-15 mmHg)Device
Patient will wear low grade compression stockings (10-15 mmHg) at least 8 hours a day 5 days a week
high grade compression stockings (20-30 mmHg)Device
Patient will wear low grade compression stockings (20-30 mmHg) at least 8 hours a day 5 days a week
| Study group | Role | What they receive |
|---|---|---|
| low grade compression stocking arm | Placebo comparator | Patients will be assigned to receive 2 pairs of low grade compression stockings (10-15 mmHg), that they will be wearing at least 8 hours a day 5 days a week. Receives: Device: low grade compression stockings (10-15 mmHg) |
| high grade compression stocking arm | Experimental | Patients will be assigned to receive 2 pairs of high grade compression stockings (20-30 mmHg), that they will be wearing at least 8 hours a day 5 days a week. Receives: Device: high grade compression stockings (20-30 mmHg) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of adverse events.
The number of adverse events (deaths and hospitalizations) will be recorded and compared between each group.
Measured: 3 months
Change in symptoms of heart failure.
This outcome measures the changes in the Kansas City Cardiomyopathy Questionnaire (KCCQ) scores from each group. KCCQ scores are from 0-100. The higher the score the better the patient is.
Measured: 3 months
Change in kidney function.
This outcome measures the change in BUN and creatinine from each group. BUN and creatinine will be measured in mg/dl.
Measured: 3 months
Secondary outcomes (3)
Change in venous reflux.
This outcome measures the change in valve closure time (VCT) in milliseconds between the two groups.
Measured: 3 months
Change in C Class from the CEAP classification for venous insufficiency.
C class range from C0 to C6 and describe the clinical signs of venous insufficiency. This outcome will measure the difference of C class between both groups.
Measured: 3 months
Mobility of the patient
To measure mobility the Short Physical Performance Battery (SPPB) test is used. The test scores from 0-12. This outcome compares change in SPPB scores between both groups.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Apr 2024
- Study start17 Jan 2024
- Primary completion1 Jun 2025 (estimated)
- Study completion1 Jan 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart Failure,CongestiveStudies of the same condition, open and under way.
- More trials run by University of Maryland, BaltimoreThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a prospective randomized-control 1:1 single blind study
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Maryland, Baltimore
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Aging (NIA), University of Texas Southwestern Medical Center
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06350695
- Sponsor's protocol ID
- HP-00103478
- Other IDs
- 1R21AG080424-01
- Acronym
- ROCK-HF
- Status last verified
- Sep 2024
- First submitted
- 18 Mar 2024
- Last updated
- 2 Oct 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: Data collected during the course of this study will be published in archival journals and presented at relevant conferences and society meetings. All publications will be made available in accordance with NIH policies. Furthermore, all complete data sets will be made available in electronic form upon request. Resource Sharing Research Resources generated with funds from this grant will be freely distributed, as available to qualified academic investigators for non-commercial research. We, and University of Maryland will adhere to the NIH Grants Policy on Sharing of Unique Research.
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The ROle of Compression StocKings in Heart Failure Patients
- ClinicalTrials.gov ID
- NCT06350695
- Acronym / sponsor ID
- ROCK-HF / HP-00103478
- Keywords
- compression stockings, congestive heart failure, venous insufficiency, edema of the legs, venous ulcers
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- University of Maryland, BaltimoreUniversity, hospital or other
- Collaborators
- National Institute on Aging (NIA), University of Texas Southwestern Medical Center
- Study start
- 17 Jan 2024 (actual)
- Primary completion
- 1 Jun 2025 (estimated)
- Study completion
- 1 Jan 2026 (estimated)
- First posted
- 5 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Congestive heart failure (CHF) occurs when the heart is weak and not able to effectively pump blood to the body. One of the common manifestations of CHF is fluid overload and swelling of the legs. Diuretics or "water pills" are usually the treatment for fluid overload and leg swelling; however, in some patients' diuretics are no longer effective or the effectiveness is limited due to poor kidney function. The presence of chronic swelling of the legs could potentially damage the veins; additionally, it could lead to chronic skin changes in the legs and in the worst cases to a leg ulcer. Compression stockings are used in patients with venous diseases to reduce the swelling of the legs and improve mobility and quality of life. Although, there is a theoretical risk that compression stockings might push the fluid of the legs back to the heart and lungs worsening the CHF. The purpose of this study is to determine whether the use of knee-high tight socks (tight stockings with strong compression) vs. knee-high soft socks (soft stockings with minimum compression) are effective in preventing swelling and skin changes and safe in patients with CHF. During the first visit (in-person) a routine medical test will be performed including blood tests, review of the medication doses, current weight, an ultrasound images of the veins, (venous reflux ultrasound), questions about health status and a brief physical exam. The participants will be randomly assigned to receive tight compression vs. soft compression socks. Participants will be asked to wear the socks at least 8 hours a day for 5 days a week. There will be a total of 3 virtual visit (by video or telephone); the first one after one week, then after one month and two months. During the virtual visit participants will be asked about symptoms, current medications and doses, and current weight. The participants are expected to return to the clinic after 3 months for a second in-person visit. During this visit the investigators will ask questions about participant's health, they will perform a brief physical exam of their legs, and check participants weight and medicines; also, a venous ultrasound of the legs, questions about health status will be performed. The duration of the study is 3 months.
Detailed description
Introduction Heart failure (HF) affects 6.2 million patients in the United States and was responsible of 13.4% of deaths in 2018 costing about 30.7 billion USD in 2012, and about 80% of all the patients with HF are \>65 years old. Clinical manifestations include shortness of breath and peripheral edema. Diuretics are indicated to treat edema in patients with HF, however, its use is limited in patients with compromised kidney function. Peripheral edema is associated with pain, heavy legs, limited mobility, and poor quality of life, increasing the risk of cellulitis, and wounds. Heart failure was identified in up to 44% of patients with venous ulcers. The chronic use of compression stockings in HF patients has potential benefits such as a better control of the edema, decreasing the need for diuretics, improving mobility, prevention of progression of venous disease, and prevention of venous ulcers. To date, no major HF guidelines recommend in favor or against compression stockings in HF patients.
Previous studies in patients with HF who had a pulmonary artery catheter in place, showed that compression of the lower extremities increases the right atrial pressure. However, it was a short intervention, and there was no evidence of clinical deterioration or worsening symptoms of HF. A retrospective review from a wound center showed that the use of compression therapy in HF patient was not associated with an increase in death, hospitalizations, or use of diuretics.
Hypothesis: The hypothesis is the use of compression stockings would prevent developing or worsening venous disease (venous reflux, and venous ulcers), improving the edema of the lower extremities, mobility and quality of life in HF patients without increasing the risk of HF deterioration, hospitalization, or death. To obtain preliminary information, this study proposes to randomize 30 patients with HF (New York Heart Association class II-III, stage A, B or C) on maximum medical therapy to 3 months of compression stockings 20-30 mmHg knee high (High compression group, n=15) vs. regular stocking with ≤10 mmHg of compression (Low compression group, n=15).
Aim 1. To determine whether the use of graduated 20-30 mmHg compression stockings are associated with clinical deterioration or increase is hospitalization or death in patients with HF. Patients will be evaluated at baseline, in a week after enrollment (telemedicine), and at three months. The New York Heart Association (NYHA) clinical classification, the Kansas City Cardiomyopathy Questionnaire (KCCQ), levels of brain natriuretic peptide, serum creatinine, documentation of diuretic therapy, body weight, visits to the Emergency Department, hospitalizations and deaths will be obtained on the baseline and 3-month visit. The change in NYHA clinical classification, KCCQ, body weight, diuretic dosage and any adverse events will be compared at 3 months.
AIM 2a. To evaluate if the use of graduated 20-30 mmHg compression stockings is associated with prevention of developing or worsening venous reflux. The presence of venous reflux will be documented with a venous duplex of the lower extremities looking for reflux and obstruction. The difference in time (3-month - baseline) of venous valve closure in milliseconds in bilateral common iliac, common femoral, femoral, popliteal veins, saphenous-femoral junction, great saphenous and small saphenous veins will be documented and compared between high compression and low compression stocking groups.
AIM 2b. To evaluate if the use of graduated 20-30 mmHg compression stockings is associated with prevention of developing or worsening clinical signs of venous insufficiency (C class of CEAP C1-C6). A brief physical exam of the lower extremities will be performed to obtain the C class for the CEAP classification for venous disease at baseline and 3 months. The C score will be compared between high compression and low compression stocking groups.
Aim 3. To evaluate if the use of graduated 20-30 mmHg compression stockings is associated with improvement of mobility and quality of life in heart failure patients. The quality of life will be documented using the VEINS QoL and SF-36 questionnaires; and the mobility will be assessed using the Short Physical Performance Battery test (SPPB). Patients will be evaluated at baseline and at 3-months visits. The difference in scores (3-month - baseline) will be compared between high compression and low compression stocking groups.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- This is a prospective randomized-control 1:1 single blind study
| Arm | Type | Receives |
|---|---|---|
| low grade compression stocking arm | Placebo comparator | Device: low grade compression stockings (10-15 mmHg)Patients will be assigned to receive 2 pairs of low grade compression stockings (10-15 mmHg), that they will be wearing at least 8 hours a day 5 days a week. |
| high grade compression stocking arm | Experimental | Device: high grade compression stockings (20-30 mmHg)Patients will be assigned to receive 2 pairs of high grade compression stockings (20-30 mmHg), that they will be wearing at least 8 hours a day 5 days a week. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age 18 years and older
- Diagnosis of Heart failure NYHA II-III Class A, B, or C.
- Pitting edema of the lower extremities
Key exclusion criteria (14 listed)
- Peripheral arterial disease with ABI of 0.5 or less
- Severe decompensated heart failure NYHA IV
- Unstable acute coronary syndrome
- Severe valvular stenosis or regurgitation
- Hypertrophic obstructive cardiomyopathy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| low grade compression stockings (10-15 mmHg)Patient will wear low grade compression stockings (10-15 mmHg) at least 8 hours a day 5 days a week | Device | low grade compression stocking arm |
| high grade compression stockings (20-30 mmHg)Patient will wear low grade compression stockings (20-30 mmHg) at least 8 hours a day 5 days a week | Device | high grade compression stocking arm |
Primary outcome
Incidence of adverse events.
Time frame: 3 months
The number of adverse events (deaths and hospitalizations) will be recorded and compared between each group.
Change in symptoms of heart failure.
Time frame: 3 months
This outcome measures the changes in the Kansas City Cardiomyopathy Questionnaire (KCCQ) scores from each group. KCCQ scores are from 0-100. The higher the score the better the patient is.
Change in kidney function.
Time frame: 3 months
This outcome measures the change in BUN and creatinine from each group. BUN and creatinine will be measured in mg/dl.
3 secondary outcomes
Change in venous reflux.
Time frame: 3 months
Change in C Class from the CEAP classification for venous insufficiency.
Time frame: 3 months
Mobility of the patient
Time frame: 3 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2024.
- Individual participant dataSharing planned: Yes. Data collected during the course of this study will be published in archival journals and presented at relevant conferences and society meetings. All publications will be made available in accordance with NIH policies. Furthermore, all complete data sets will be made available in electronic form upon request. Resource Sharing Research Resources generated with funds from this grant will be freely distributed, as available to qualified academic investigators for non-commercial research. We, and University of Maryland will adhere to the NIH Grants Policy on Sharing of Unique Research.
Related trials for Heart Failure,Congestive
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Recruiting
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)
Heart Failure
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing low grade compression stockings (10-15 mmHg) and high grade compression stockings (20-30 mmHg) in people with Heart Failure,Congestive and Leg Edema, run by University of Maryland, Baltimore at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 2 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Rafael S Cires-Drouet, MD (2146452174, rafael.cires-drouet@UTSouthwestern.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of adverse events. (time frame: 3 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2024.